Get started
Author

Victoria A. Gaeth

Observed name: Victoria Gaeth
ORCID: 0009-0006-9297-3898
Observed ORCID: 0009-0006-9297-3898
OpenAlex ID: A5093689428
FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
2025 · Claudia Tonelli, Astrid Deschênes, et al. · Cancer Research · 7
PDF
Whole-Genome Sequencing and Annotation of 10 Endophytic and Epiphytic Bacteria Isolated from Lolium arundinaceum
2021 · Victoria A. Gaeth, Christina J. Domondon, et al. · Microbiology Resource Announcements · 2
Abstract B068: FYN and other Src family kinases antagonize response to RAS inhibition in pancreatic ductal adenocarcinoma
2026 · Hsiu-Chi Ting, Sun Y. Kim, et al. · Cancer Research
Abstract B056: SOAT1 inhibition by a covalent metabolite mimetic targets RAS maturation and pancreatic cancer
2026 · Wenjun Lan, Shoujun Sun, et al. · Cancer Research
Dual modulation of prostaglandin E2 receptors, EP3 and EP4, protects beta-cell mass in a model of aggressive autoimmune inflammation
2026 · Juliann B. Burkett, Jennifer Fuhr, et al.
Dual Modulation of Prostaglandin E2 Receptors EP3 and EP4 Protects β-Cell Mass in a Model of Aggressive Autoimmune Inflammation
2026 · Juliann B. Burkett, Jennifer Fuhr, et al. · Diabetes
PDF
Dual modulation of prostaglandin E2 receptors, EP3 and EP4, protects beta-cell mass in a model of aggressive autoimmune inflammation
2026 · Juliann B. Burkett, Jennifer Fuhr, et al.
Abstract B036: FYN antagonizes response to RAS inhibition in pancreatic ductal adenocarcinoma
2026 · Hsiu-Chi Ting, Sun Y. Kim, et al. · Cancer Research
Supplementary Figure S7 from FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
2025 · Claudia Tonelli, Astrid Deschênes, et al.
Supplementary Figure S8 from FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
2025 · Claudia Tonelli, Astrid Deschênes, et al.
Supplementary Figure S9 from FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
2025 · Claudia Tonelli, Astrid Deschênes, et al.
PDF
Supplementary Figure S1 from FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
2025 · Claudia Tonelli, Astrid Deschênes, et al.
Supplementary Figure S6 from FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
2025 · Claudia Tonelli, Astrid Deschênes, et al.
Supplementary Table S2 from FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
2025 · Claudia Tonelli, Astrid Deschênes, et al.
Supplementary Table S3 from FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
2025 · Claudia Tonelli, Astrid Deschênes, et al.
Supplementary Figure S2 from FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
2025 · Claudia Tonelli, Astrid Deschênes, et al.
PDF
Supplementary Table S1 from FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
2025 · Claudia Tonelli, Astrid Deschênes, et al.
Supplementary Figure S4 from FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
2025 · Claudia Tonelli, Astrid Deschênes, et al.
Supplementary Figure S5 from FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
2025 · Claudia Tonelli, Astrid Deschênes, et al.
Data from FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
2025 · Claudia Tonelli, Astrid Deschênes, et al.
Supplementary Figure S3 from FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
2025 · Claudia Tonelli, Astrid Deschênes, et al.
Abstract B008: Secretome labeling identifies gelsolin as a potential pro-tumorigenic PDAC biomarker
2024 · Jonathan P. Kastan, Oliver Standring, et al. · Cancer Research
Abstract B081: SOAT1 as a targetable KRAS dependency in PDAC
2024 · Wenjun Lan, Shoujun Sun, et al. · Cancer Research
Works count: 23
Citation count: 8
H-index: 2
I10-index:
Year
Topic
Type